{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:09:33Z","timestamp":1793642973551,"version":"4.5.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"JSPS KAKENHI","award":["22K08368"],"award-info":[{"award-number":["22K08368"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12325-022-02223-0","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T09:04:19Z","timestamp":1656147859000},"page":"3488-3500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1250-7437","authenticated-orcid":false,"given":"Akira","family":"Mima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"issue":"14","key":"2223_CR1","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977\u201386.","journal-title":"N Engl J Med"},{"key":"2223_CR2","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type\u00a02 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837\u201353.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"issue":"9","key":"2223_CR3","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/labinvest.3700445","volume":"86","author":"A Mima","year":"2006","unstructured":"Mima A, Matsubara T, Arai H, et al. Angiotensin\u00a0II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy. Lab Investig. 2006;86(9):927\u201339.","journal-title":"Lab Investig"},{"issue":"6","key":"2223_CR4","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.2337\/db08-0061","volume":"57","author":"Y Qian","year":"2008","unstructured":"Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius FC 3rd. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes. 2008;57(6):1439\u201345.","journal-title":"Diabetes"},{"issue":"6","key":"2223_CR5","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.2337\/db07-1726","volume":"57","author":"A Mima","year":"2008","unstructured":"Mima A, Arai H, Matsubara T, et al. Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy. Diabetes. 2008;57(6):1712\u201322.","journal-title":"Diabetes"},{"issue":"7","key":"2223_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1056\/NEJM198302173080709","volume":"308","author":"WB Blythe","year":"1983","unstructured":"Blythe WB. Captopril and renal autoregulation. N Engl J Med. 1983;308(7):390\u20131.","journal-title":"N Engl J Med"},{"issue":"1","key":"2223_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/ki.1987.174","volume":"32","author":"JE Heeg","year":"1987","unstructured":"Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int. 1987;32(1):78\u201383.","journal-title":"Kidney Int"},{"issue":"20","key":"2223_CR8","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456\u201362.","journal-title":"N Engl J Med"},{"issue":"12","key":"2223_CR9","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type\u00a02 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"2223_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type\u00a02 diabetes. N Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med"},{"issue":"18","key":"2223_CR11","first-page":"1801","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type\u00a02 diabetes. N Engl J Med. 2016;375(18):1801\u20132.","journal-title":"N Engl J Med"},{"issue":"24","key":"2223_CR12","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"2223_CR13","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"9","key":"2223_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type\u00a02 diabetes. N Engl J Med. 2017;377(9):839\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"2223_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type\u00a02 diabetes and high cardiovascular and renal risk: the CARMELINA Randomized clinical trial. JAMA. 2019;321(1):69\u201379.","journal-title":"JAMA"},{"issue":"23","key":"2223_CR16","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type\u00a02 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"2223_CR17","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type\u00a02 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"issue":"11","key":"2223_CR18","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.2337\/db11-1824","volume":"61","author":"A Mima","year":"2012","unstructured":"Mima A, Hiraoka-Yamomoto J, Li Q, et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes. 2012;61(11):2967\u201379.","journal-title":"Diabetes"},{"key":"2223_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/248563","volume":"2013","author":"A Mima","year":"2013","unstructured":"Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res. 2013;2013: 248563.","journal-title":"J Diabetes Res"},{"issue":"4","key":"2223_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.kint.2020.06.024","volume":"98","author":"IH de Boer","year":"2020","unstructured":"de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney Int. 2020;98(4):839\u201348.","journal-title":"Kidney Int"},{"issue":"12","key":"2223_CR21","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1111\/dom.14158","volume":"22","author":"C Wanner","year":"2020","unstructured":"Wanner C, Inzucchi SE, Zinman B, et al. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: insights from the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2020;22(12):2335\u201347.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2223_CR22","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1681\/ASN.V10122569","volume":"10","author":"V Vallon","year":"1999","unstructured":"Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999;10(12):2569\u201376.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2223_CR23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter\u00a02 inhibition in patients with type\u00a01 diabetes mellitus. Circulation. 2014;129(5):587\u201397.","journal-title":"Circulation"},{"issue":"7","key":"2223_CR24","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jdiacomp.2018.04.011","volume":"32","author":"A Mima","year":"2018","unstructured":"Mima A. Renal protection by sodium-glucose cotransporter\u00a02 inhibitors and its underlying mechanisms in diabetic kidney disease. J Diabetes Complicat. 2018;32(7):720\u20135.","journal-title":"J Diabetes Complicat"},{"issue":"5","key":"2223_CR25","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s12325-021-01735-5","volume":"38","author":"A Mima","year":"2021","unstructured":"Mima A. Sodium-glucose cotransporter\u00a02 inhibitors in patients with non-diabetic chronic kidney disease. Adv Ther. 2021;38(5):2201\u201312.","journal-title":"Adv Ther"},{"issue":"8","key":"2223_CR26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/ki.2010.526","volume":"79","author":"A Mima","year":"2011","unstructured":"Mima A, Ohshiro Y, Kitada M, et al. Glomerular-specific protein kinase C-beta-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. Kidney Int. 2011;79(8):883\u201396.","journal-title":"Kidney Int"},{"issue":"5","key":"2223_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.semnephrol.2012.07.010","volume":"32","author":"A Mima","year":"2012","unstructured":"Mima A, Qi W, King GL. Implications of treatment that target protective mechanisms against diabetic nephropathy. Semin Nephrol. 2012;32(5):471\u20138.","journal-title":"Semin Nephrol"},{"issue":"5","key":"2223_CR28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jdiacomp.2013.03.003","volume":"27","author":"A Mima","year":"2013","unstructured":"Mima A. Diabetic nephropathy: protective factors and a new therapeutic paradigm. J Diabetes Complicat. 2013;27(5):526\u201330.","journal-title":"J Diabetes Complicat"},{"issue":"13","key":"2223_CR29","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1167\/iovs.12-10207","volume":"53","author":"A Mima","year":"2012","unstructured":"Mima A, Qi W, Hiraoka-Yamomoto J, et al. Retinal not systemic oxidative and inflammatory stress correlated with VEGF expression in rodent models of insulin resistance and diabetes. Investig Ophthalmol Vis Sci. 2012;53(13):8424\u201332.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"4","key":"2223_CR30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/2211-5463.12400","volume":"8","author":"A Mima","year":"2018","unstructured":"Mima A, Yasuzawa T, King GL, Ueshima S. Obesity-associated glomerular inflammation increases albuminuria without renal histological changes. FEBS Open Bio. 2018;8(4):664\u201370.","journal-title":"FEBS Open Bio"},{"key":"2223_CR31","doi-asserted-by":"publisher","first-page":"26428","DOI":"10.1038\/srep26428","volume":"6","author":"LA Gallo","year":"2016","unstructured":"Gallo LA, Ward MS, Fotheringham AK, et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db\/db mice. Sci Rep. 2016;6:26428.","journal-title":"Sci Rep"},{"issue":"4","key":"2223_CR32","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1167\/iovs.11-8447","volume":"53","author":"D Gambhir","year":"2012","unstructured":"Gambhir D, Ananth S, Veeranan-Karmegam R, et al. GPR109A as an anti-inflammatory receptor in retinal pigment epithelial cells and its relevance to diabetic retinopathy. Investig Ophthalmol Vis Sci. 2012;53(4):2208\u201317.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"6116","key":"2223_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1126\/science.1227166","volume":"339","author":"T Shimazu","year":"2013","unstructured":"Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339(6116):211\u20134.","journal-title":"Science"},{"issue":"3","key":"2223_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153\u201365.","journal-title":"Cell Metab"},{"issue":"7","key":"2223_CR35","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","volume":"137","author":"BP Bullock","year":"1996","unstructured":"Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137(7):2968\u201378.","journal-title":"Endocrinology"},{"issue":"4","key":"2223_CR36","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1681\/ASN.2006070778","volume":"18","author":"CW Park","year":"2007","unstructured":"Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db\/db mice. J Am Soc Nephrol. 2007;18(4):1227\u201338.","journal-title":"J Am Soc Nephrol"},{"issue":"1\u20132","key":"2223_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.mce.2010.04.022","volume":"325","author":"O Erdogdu","year":"2010","unstructured":"Erdogdu O, Nathanson D, Sjoholm A, Nystrom T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K\/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol. 2010;325(1\u20132):26\u201335.","journal-title":"Mol Cell Endocrinol"},{"key":"2223_CR38","doi-asserted-by":"publisher","first-page":"1379274","DOI":"10.1155\/2016\/1379274","volume":"2016","author":"A Mima","year":"2016","unstructured":"Mima A. Incretin-based therapy for prevention of diabetic vascular complications. J Diabetes Res. 2016;2016:1379274.","journal-title":"J Diabetes Res"},{"issue":"1","key":"2223_CR39","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1038\/s41598-020-62579-7","volume":"10","author":"A Mima","year":"2020","unstructured":"Mima A, Yasuzawa T, Nakamura T, Ueshima S. Linagliptin affects IRS1\/Akt signaling and prevents high glucose-induced apoptosis in podocytes. Sci Rep. 2020;10(1):5775.","journal-title":"Sci Rep"},{"issue":"7","key":"2223_CR40","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1096\/fj.11-202994","volume":"26","author":"A Mima","year":"2012","unstructured":"Mima A, Kitada M, Geraldes P, et al. Glomerular VEGF resistance induced by PKCdelta\/SHP-1 activation and contribution to diabetic nephropathy. FASEB J. 2012;26(7):2963\u201374.","journal-title":"FASEB J"},{"issue":"6","key":"2223_CR41","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.2337\/db13-1029","volume":"63","author":"K Kanasaki","year":"2014","unstructured":"Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63(6):2120\u201331.","journal-title":"Diabetes"},{"key":"2223_CR42","doi-asserted-by":"publisher","first-page":"2182225","DOI":"10.1155\/2021\/2182225","volume":"2021","author":"T Yasuzawa","year":"2021","unstructured":"Yasuzawa T, Nakamura T, Ueshima S, Mima A. Protective effects of eicosapentaenoic acid on the glomerular endothelium via inhibition of EndMT in diabetes. J Diabetes Res. 2021;2021:2182225.","journal-title":"J Diabetes Res"},{"issue":"10","key":"2223_CR43","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11906-017-0778-2","volume":"19","author":"S Culver","year":"2017","unstructured":"Culver S, Li C, Siragy HM. Intrarenal angiotensin-converting enzyme: the old and the new. Curr Hypertens Rep. 2017;19(10):80.","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"2223_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2174\/1574884713666181116100946","volume":"14","author":"L Goenka","year":"2019","unstructured":"Goenka L, Padmanaban R, George M. The ascent of mineralocorticoid receptor antagonists in diabetic nephropathy. Curr Clin Pharmacol. 2019;14(2):78\u201383.","journal-title":"Curr Clin Pharmacol"},{"key":"2223_CR45","first-page":"CD007004","volume":"4","author":"D Bolignano","year":"2014","unstructured":"Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4:CD007004.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2223_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","volume":"17","author":"G Currie","year":"2016","unstructured":"Currie G, Taylor AH, Fujita T, et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016;17(1):127.","journal-title":"BMC Nephrol"},{"issue":"5","key":"2223_CR47","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","volume":"67","author":"J Grune","year":"2016","unstructured":"Grune J, Benz V, Brix S, et al. Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 2016;67(5):402\u201311.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"2223_CR48","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension. 2018;71(4):599\u2013608.","journal-title":"Hypertension"},{"issue":"1","key":"2223_CR49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2223_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174583","volume":"912","author":"A Mima","year":"2021","unstructured":"Mima A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: advantages and disadvantages. Eur J Pharmacol. 2021;912: 174583.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2223_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e08878","volume":"8","author":"A Mima","year":"2022","unstructured":"Mima A. Mitochondria-targeted drugs for diabetic kidney disease. Heliyon. 2022;8(2): e08878.","journal-title":"Heliyon"},{"issue":"5","key":"2223_CR52","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","volume":"69","author":"L Lattenist","year":"2017","unstructured":"Lattenist L, Lechner SM, Messaoudi S, et al. Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress. Hypertension. 2017;69(5):870\u20138.","journal-title":"Hypertension"},{"issue":"4","key":"2223_CR53","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1681\/ASN.2016040477","volume":"28","author":"J Barrera-Chimal","year":"2017","unstructured":"Barrera-Chimal J, Andre-Gregoire G, Nguyen DinhCat A, et al. Benefit of mineralocorticoid receptor antagonism in AKI: role of vascular smooth muscle Rac1. J Am Soc Nephrol. 2017;28(4):1216\u201326.","journal-title":"J Am Soc Nephrol"},{"issue":"31","key":"2223_CR54","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363.","journal-title":"Eur Heart J"},{"key":"2223_CR55","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter. 2013;(Suppl 3):1\u2013150."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02223-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02223-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02223-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T15:35:25Z","timestamp":1658676925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02223-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2223"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02223-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,25]]},"assertion":[{"value":"22 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}